CARETEQ LIMITED — Director's Dealing 2022

Apr 28, 2022

Careteq Limited ACN 612 267 857

==> picture [144 x 38] intentionally omitted <==

Level 10, 99 Queen St Melbourne 3000 info@careteq.com.au Phone: 1300 110 366 International: +613 8866 5594

29[th] April 2022

The Manager Market Announcements Platform Australian Securities Exchange Limited

APPENDIX 3X CORRECTION - M SIMARI

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) advises the following in relation to the Appendix 3X as lodged for Mr Simari on 11 January 2022:

• The Appendix 3X was inadvertently incorrect due to an administrative oversight.

• In addition to the interests disclosed in the above mentioned Appendix 3X Mr Simari as trustee for his minor children holds an additional 50,000 ordinary shares.

• The Company took immediate steps to address this oversight on realisation that the Appendix 3X. The Company advises that it is aware of its Listing Rules obligations in relation to these disclosures and specifically Listing Rule 3.19A.

• The Company has put in place an update to its set procedure to ensure that the Company and its Directors are able to meet their disclosure obligations under Listing Rule 3.19A.

• The Company has reviewed its previous procedures and now considers that its revised arrangements are adequate for ensuring timely notification and compliance.

This announcement has been approved by the Board of Directors.

Subscribe to receive investor updates by emailing : investors@careteq.com.au

For investor and media enquiries, please contact:

Brendon Lau E: brendon@vantagepointpartners.com.au M: +61 409 341 613

About Careteq Limited

Careteq is an Australian-headquartered health-tech company that has developed and commercialised a suite of products that sit on its proprietary SaaS-based Assistive Living Technology platform for use by the elderly, disabled and vulnerable individuals. Its products and services, which improve outcomes for patients and their carers while increasing productivity, are sold in Australia and internationally through industry leading distributors and specialist retailers. Careteq generates revenues from recurring platform subscriptions, contracted medication management services and sales of its innovative range of sensors and devices that detect falls or unusual behaviour, monitor patient health, provide SOS emergency call functionality and deliver medication reminders. Careteq is using its earlymover advantage in the Assistive Living Technology sector to revolutionise aged and disability care. For more information about Careteq, visit https://www.careteq.com.au/.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Careteq Limited ABN 83 612 267 857

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Simari
Date of last notice	9 February 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	1. Charkaroo Pty Ltd2. Jodmar Pty Ltd3. Mark Simari
Date of change	29 April 2022
No. of securities held prior to change	Charkaroo Pty Ltd1. 3,477,992 Fully paid ordinaryshares2. 1,168,965Unlistedoptions(exercise price $0.094 and expirydate 15 December 2023)Jodmar Pty Ltd1. 1,189,286 Fully paid ordinarysharesMark Simari1. 50,000 Fully paid ordinary shares
Class	Fully paid ordinary shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	851,844 Fully paid ordinary shares
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	851,844 shares at $0.1201 per share
No. of securities held after change	Charkaroo Pty Ltd3. 4,329,836 Fully paid ordinaryshares4. 1,168,965Unlistedoptions(exercise price $0.094 and expirydate 15 December 2023)Jodmar Pty Ltd2. 1,189,286 Fully paid ordinarysharesMark Simari2. 50,000 Fully paid ordinary shares
Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back	On market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Detail of contract	Detail of contract	N/A	N/A	N/A	N/A
	Nature of interest		N/A
	N f id hld		NA
	ame o regstere oer(if issued securities)		/
	D f h		NA
	ate o cange		/
	No and class of securities to	hich	N/A
	.interest related prior to chang	e
	Note: Details are only required for a contrelation to which the interest has changed	ract in
	Interest acquired		N/A
	Interest disosed		N/A
	p

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?	N/A
If prior written clearance was provided, on what date wasthis provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3